For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of human gastric juice protein BPC. Its full designation in the research literature is the “stable gastric pentadecapeptide BPC 157,” reflecting that it was engineered to remain stable in gastric fluid, unlike the parent protein (World Journal of Gastroenterology). Structurally, it falls into the broader class of body-protective/cytoprotective peptides studied primarily in rodent injury models rather than as a naturally circulating human hormone.
Summary of Published Preclinical Research
The largest body of BPC-157 literature originates from gastrointestinal and musculoskeletal injury models in rats. In one foundational study, researchers administered BPC-157 intramuscularly and intragastrically to rats with chemically induced acute and chronic gastric ulcers, finding that treated animals showed significantly reduced ulcer area (inhibition ratios of roughly 46–66%) compared to controls, with intramuscular dosing outperforming a reference compound (famotidine) in several measures (World Journal of Gastroenterology, 2004).
In musculoskeletal research, a widely cited rat study by Staresinic et al. examined transected Achilles tendons and found that BPC-157 administration was associated with accelerated functional recovery and improved tendon-to-bone healing markers compared to untreated controls (Staresinic 2003 study summary). A related rat model examining Achilles tendon detachment reported that BPC-157 promoted tendon-to-bone healing and counteracted the negative healing effects induced by corticosteroid administration (PubMed, PMID 16583442). A more recent narrative review consolidates this tendon/ligament dataset and discusses the consistency of pro-healing findings across multiple rodent injury models while also flagging translational uncertainties (narrative review of BPC-157).
Additional rodent research has explored BPC-157 in models of impaired healing, including studies characterizing its activity in models with compromised vascular healing responses (PMID 18668315 and PMID 34829776).
Proposed Mechanism of Action
Across the published rodent literature, BPC-157’s effects are most frequently attributed to modulation of the nitric oxide (NO) signaling system, with several studies reporting that BPC-157 interacts with the NO pathway to influence vascular tone and angiogenesis (blood vessel formation) at injury sites (PMC11768438). Researchers have also proposed that BPC-157 supports fibroblast activity and granulation tissue organization during tendon and ligament repair processes observed in the transection and detachment models cited above. In gastric ulcer models, proposed mechanisms include cytoprotective effects on the gastric mucosal lining and modulation of the gut-brain axis. It is important to note that a definitive, universally accepted molecular mechanism has not been established, and most proposed pathways are drawn from rodent and in-vitro observational data rather than confirmed human pharmacodynamics.
Research Use Only / Handling Note
This product is intended strictly for in-vitro and laboratory research applications by qualified personnel. It is supplied as a lyophilized (freeze-dried) powder. This material is not a drug, dietary supplement, or cosmetic, and is not for human or animal consumption.